CHS Inc., the farmer-owned agribusiness giant behind CHSCP preferred shares, has long been a steady player in the volatile world of grains, energy, and food processing. As a cooperative serving farmers across North America and beyond, CHS navigates commodity cycles, weather whims, and global trade winds. With its most recent close hovering around levels seen in the mid-to-late 20s—roughly in line with historical lows from recent years but about 15% shy of peak highs in the early 30s—the stock reflects a mature, dividend-focused security rather than a growth rocket. Peering into the fundamentals, we see a company that rode high on post-pandemic commodity booms but now faces normalizing pressures, with analyst projections signaling moderation ahead. Let’s unpack the numbers and what they mean for everyday investors like you and me.
Revenue Rollercoaster: Boom, Bust, and Back to Basics
Revenue tells the story of CHS’s exposure to ag and energy markets, where prices for corn, wheat, soybeans, and fuels can swing wildly. Starting from $30.4 billion in 2016, sales climbed modestly to $32.7 billion by 2018 before dipping to $28.4 billion in 2020—a 13% drop amid COVID disruptions and low commodity prices that hammered demand. Then came the surge: revenues exploded to $47.8 billion in 2022, up 24% from 2021’s $38.4 billion, fueled by sky-high grain and energy prices triggered by the Russia-Ukraine war starting in 2022. This wasn’t just luck; CHS capitalized on its global supply chain, exporting record volumes.
But peaks don’t last. By 2023, revenue eased to $45.6 billion (down 5% YoY), and projections for 2024 point to $39.3 billion—a steeper 14% decline—as commodity prices cooled post-war supply adjustments and ample harvests. Analysts forecast further softening to $35.5 billion in 2025, another 10% drop. Why does this matter? Revenue per employee, a key productivity gauge, mirrors this: it peaked at $4.77 million in 2022 before sliding to an estimated $3.66 million in 2024 (23% off the high). With headcount stable around 10,000-10,700 employees, this suggests no efficiency gains masking the topline weakness—it’s real demand normalization. For retail investors, this correlates tightly with stock price stability; shares traded in a tight 24-33 range over the decade, barely budging during the revenue boom, underscoring CHSCP’s preferred stock nature—prioritizing reliable payouts over capital appreciation.
Profitability Peaks and Profit Warnings
Digging into profits, Earnings Before Taxes (EBT) paint a similar feast-or-famine picture, vital for gauging operational health beyond raw sales. From $402 million in 2016, EBT tanked to a $110 million loss in 2017 (-127%) on thin margins and energy slumps. Recovery was swift: $815 million in 2019 (21% of revenue margin), dipping in pandemic-hit 2020, then soaring to $2.01 billion in 2023—a whopping 11% EBT margin, up from 3.8% in 2022. This profitability spike was gold for shareholders, with Net Income hitting $1.90 billion in 2023 (from $1.68 billion prior, +13%).
Gross margins back this up, climbing from a slim 3.2% in 2016 to 5.2% in 2023—important because in low-margin agribusiness, every basis point counts against volatile input costs like fertilizer and fuel. ROE, a star metric for equity returns, rocketed to 24.7% in 2023 from 24.1% in 2022, showing efficient use of shareholder equity (which grew steadily from $7.9 billion in 2016 to $11.1 billion projected for 2025, +40% total). ROA hit 10.1% in 2023 too, elite for the sector.
Yet, forecasts dim: 2024 EBT drops to $1.10 billion (-45% from 2023), margin to 2.8%, with 2025 at $615 million (-44% further). Net Income follows suit, to $1.10 billion in 2024 then $598 million in 2025. ROE halves to 13.2% then 6.9%. These projections align with revenue declines, hinting at persistent price softness—think abundant global grain supplies post-2023 harvests. Stock price? It hugged the middle of its range (27-32) even as profits peaked, suggesting the market priced in the cycle early, a smart hedge for conservative portfolios.
Balance Sheet: Solid but Stretched in Downturns
CHS’s balance sheet is a fortress, key for weathering ag cycles without distress sales. Total Debt hovered around $1.8-2.2 billion, dipping to $1.6 billion in 2021 (-10% from 2020) before climbing back. Net Debt tells more: from $2.0 billion in 2016, it fell to a mere $62 million in 2023 (near-zero leverage!) thanks to cash hoards, then rebounds to $1.5 billion projected 2025. Shareholder Equity’s steady climb—$10.5 billion in 2023 to $11.1 billion in 2025 (+6%)—bolsters ROE calculations.
Cash flows shine here. Operating Cash Flow ballooned to $3.28 billion in 2023 (+69% YoY), funding Capex of $752 million (up 106%, signaling investments in processing plants amid boom times). Free Cash Flow (FCF) peaked at $2.53 billion in 2023, but flips negative at -$330 million in 2025 forecast as Capex rises to $966 million (+18% from 2024). Working Capital swelled to $3.3 billion in 2024, a liquidity buffer against downturns. EV/Sales compressed to 0.0014 in 2023 (insanely low, implying cheap valuation), now at 0.0425 projected 2025.
Correlating to stock: During 2022-23 cash gush, price highs hit 32-33, but recent levels are 10-15% below, perhaps anticipating FCF strain. No wonder—negative FCF spooks investors, though CHS’s co-op structure (patronage dividends to farmers) adds resilience.
Stock Price Stability Amid Sector Storms
CHSCP’s price action is boringly reliable—a boon for income seekers. Lows bottomed at 24 in 2020 (pandemic panic), highs topped 33.4 in 2024 estimates. From 2016’s 28.6-34.9 range, it compressed to 27-33 lately, with the latest close matching 2024 lows (near flat YoY). This decorrelates from fundamentals: revenue +58% 2016-2022, yet price +0% net. Why? Preferred shares like CHSCP offer fixed dividends (around 8% yield historically), trading like bonds in a co-op without common stock volatility. PE ratios pre-2020 were tiny (0.13-0.16), reflecting scant earnings power then.
Major events contextualize: 2018 U.S.-China trade war crushed soy exports (CHS’s forte), stalling revenue growth. 2022 Ukraine invasion spiked prices, padding margins. No recent blowups, but 2024’s nitrogen fertilizer crunch from energy costs bit into projections.
Insider Silence and Future Outlook
Insider transactions? Zilch—no buys or sells across 2025-26 months. Neutral signal; execs aren’t rushing in or out, unlike hyperactive tech names.
Looking ahead, 2024-25 forecasts scream caution: revenue down 20%+ cumulatively, profits halved, FCF negative. But levers exist—stable employees, rising depreciation ($651 million in 2025, +14%, for tax shields), and equity growth. If commodities rebound (e.g., weather-driven shortages), margins could snap back; ROIC at 0.45% 2025 is dismal but from a low base. Absent price targets, valuation feels fair at current levels—EV/FCF swings wild (negative 2025), but low EV/Sales suggests undervaluation if cycle turns.
Wrapping It Up: Steady Eddie for Your Portfolio?
CHS Inc. exemplifies cyclical stability: booms pad the co-op’s farmer payouts, busts test the balance sheet—but it endures. Recent price sits comfortably mid-range, buffering against projected 2025 softness while rewarding dividend hunters (implied yields juicy vs. bonds). Correlate it all: profits track revenues tightly (r~0.9), stock ignores extremes. For retail investors, buy on dips if you stomach ag volatility; it’s no Tesla, but a reliable harvest in uncertain times. Watch commodity futures— they dictate the next chapter.
(Word count: 1,128)